Skip to main content

Table 2 Results of univariable and multivariable Cox regression models for overall survival (OS)

From: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma

  Number of patients Overall survival time (OS; median (CI): months) Univariable Multivariable
Hazard ratio (HR) (95% CI) p-value Hazard ratio (HR) (95% CI) p-value
Clinicopathological parameter
 Age < 64 y. 58 23.5 (12.6 - 33.0) 0.626 (0.422 - 0.924) 0.018 0.551 (0.350 - 0.859) 0.008
> 64 y. 60 13.7 (11.4 - 16.8)    
 Gender Female 53 20.5 (12.9 - 29.3) 0.865 (0.587 - 1.269) 0.459   
Male 65 12.6 (11.2 - 20.1)    
 PDAC location Head 93 19.5 (12.6 - 23.5) 0.600 (0.384 - 0.967) 0.036 0.714 (0.435 - 1.209) 0.204
Body or Tail 25 12.6 (10.0 - 26.4)    
 Tumor diameter < 2 cm 27 20.5 (11.7 - 36.5) 0.746 (0.459 - 1.165) 0.204   
> 2 cm 91 14.8 (11.9 - 20.8)    
 pG 1 10 22.5 (1.5 - 33.2)   0.89   
2 41 14.8 (11.2 - 29.3)    
3 67 15.9 (11.5 - 23.5)    
 pT 1 2 13.4 (12.3 - 14.6)   0.694   
2 13 26.9 (9.4 - 38.8)    
3 95 15.9 (11.8 - 21.0)    
4 8 12.4 (1.3 - 33.0)    
 pN 0 45 21.0 (14.6 - 29.3) 0.750 (0.499 - 1.111) 0.154   
1 73 12.8 (11.7 - 17.8)    
 pM 0 105 17.8 (12.9 - 23.5) 0.569 (0.323 - 1.097) 0.089 0.624 (0.166 - 1.928) 0.427
1 13 11.4 (5.8 - 12.4)    
 pR 0 91 16.8 (12.9 - 25.6) 0.733 (0.474 - 1.174) 0.19   
1 27 12.4 (7.0 - 23.4)    
 pRM < 1 mm 64 15.4 (11.8 - 25.6) 1.096 (0.737 - 1.622) 0.647   
> 1 mm 50 16.7 (12.3 - 23.5)    
 PNI 0 15 37.8 (10.6 - NA) 0.468 (0.227 - 0.860) 0.013 0.561 (0.252 - 1.115) 0.103
1 101 15.9 (12.4 - 20.8)    
 VI 0 36 19.7 (11.9 - 33.2) 0.730 (0.466 - 1.115) 0.148   
1 76 12.8 (11.5 - 23.4)    
 LVI 0 34 19.7 (10.6 - 33.0) 0.877 (0.561 - 1.334) 0.547   
1 81 15 (12.3 - 21.7)    
 ECLNI 0 69 20.1 (12.9 - 30.5) 0.654 (0.437 - 0.987) 0.043 0.660 (0.398 - 1.089) 0.104
1 43 12.4 (10.2 - 20.8)    
 AJCC TNM Stage 7th Ed. ≤ 2a 38 23.5 (16.8 - 31.7) 0.681 (0.443 - 1.023) 0.065 0.672 (0.166 - 2.254) 0.53
≥ 2b 80 12.6 (11.4 - 16.7)    
Early (pN=0,pT≤ 3,pM=0) 38 23.5 (16.8 - 31.7) Early vs LNM 0.722 (0.463 - 1.106) Overall 0.105   
pN=1,pT≤ 3,pM=0 62 14.8 (11.2 - 21.7) LNM vs Adv 0.736 (0.425 - 1.328) Early vs LNM 0.136   
Advanced (pT=4 or pM=1) 18 11.7 (6.6 - 12.4) Early vs Adv 0.532 (0.295 - 0.997) Early vs Adv 0.049   
 Adjuvant chemotherapy 0 36 12.1 (7.0 - 16.8) 1.337 (0.874 - 2.002) 0.176   
1 82 19.8 (13.9 - 25.6)    
Molecular subtypes
 k2 Cluster 1 64 20.9 (12.9 - 29.3) 0.710 (0.482 - 1.048) 0.081 0.247 (0.092 - 0.860) 0.031
Cluster 2 54 12.7 (11.2 - 16.7)    
 k3 Cluster 1 42 24.6 (16.8 - 33.2) Cl1 vs Cl2 0.680 (0.437 - 1.050) Overall 0.193 Overall 0.017
Cluster 2 50 12.7 (11.2 - 16.7) Cl2 vs Cl3 1.055 (0.641 - 1.788) Cl1 vs Cl2 0.082   
Cluster 3 26 11.8 (6.6 - 20.5) Cl1 vs Cl3 0.717 (0.426 - 1.236) Cl1 vs Cl3 0.226 Cl1 vs Cl3 0.209 (0.057 - 0.809) 0.024
 k4 Cluster 1 39 23.5 (14.8 - 33.0)   0.577   
Cluster 2 45 12.6 (10.6 - 16.7)    
Cluster 3 7 26.2 (9.3 - 38.8)    
Cluster 4 27 11.9 (6.6 - 21.0)    
 k5 Cluster 1 41 23.5 (14.8 - 33.2) Cl1 vs Cl5 0.398 (0.210 - 0.808) Overall 0.122 Overall 0.271
Cluster 2 35 13.9 (11.4 - 21.7) Cl2 vs Cl5 0.483 (0.251 - 0.988) Cl1 vs Cl5 0.012   
Cluster 3 4 28.9 (9.3 - NA) Cl3 vs Cl5 0.298 (0.067 - 0.949) Cl2 vs Cl5 0.046   
Cluster 4 26 11.8 (6.6 - 20.5)   Cl3 vs Cl5 0.040   
Cluster 5 12 10 (6.9 - 16.6)     
  1. Differences between variables or subgroups with a p-value of > 0.1 are not shown in the table and bold fonts indicate significant values (<0.05)